New analysis suggests NMN may slightly lower the lower blood pressure number

A fresh analysis suggests the anti-ageing supplement nicotinamide mononucleotide (NMN) led to a modest reduction in the lower figure of blood pressure readings in human studies.

That outcome keeps NMN on the clinical radar, even as better-established approaches continue to achieve much larger and more reliable falls in blood pressure.

Evidence lands softly

Looking across ten small human trials with 11 comparison arms, a signal appeared in adults whose blood pressure was already starting to creep up.

Investigators at Hangzhou Normal University in eastern China (HZNU) linked NMN with that measurable shift by comparing people given the supplement with those given inactive comparators.

The change showed up in the lower reading taken while the heart relaxes, whereas the upper reading captured during each heartbeat did not show a clear drop across the whole pooled group.

That limited split leaves NMN with an observable effect, but not yet the heft required for a full treatment claim.

Supplement targets cells

Within cells, nicotinamide mononucleotide – known as NMN – sits upstream of NAD+, a molecule cells rely on every day.

NAD+ supports the conversion of food into usable energy and helps repair damaged genetic material after day-to-day cellular stress.

Because levels commonly fall with age, firms market NMN as a way to top up that cellular reserve.

Even so, lifting a marker in the blood does not demonstrate that arteries, hearts, or real-world health outcomes will improve under normal conditions.

Pressure points matter

A drop this small can be tricky to read, since routine measurements often vary from one reading to the next.

Globally, a 2025 World Health Organization report put the number of adults aged 30–79 with high blood pressure at 1.4 billion, meaning even modest average shifts can matter at scale.

For an individual thinking about a supplement, however, a change of this size may not affect a clinician’s plan or prompt alterations to medicines.

That disconnect between population averages and personal outcomes is why the findings call for caution when making real-world choices.

Older adults stood out

In adults aged 60 and over, the review found the top blood pressure figure dipped a little more.

As arteries stiffen with age, even mild relaxation of blood vessels could register more clearly in systolic readings.

However, the signal in older adults came from a smaller portion of the evidence rather than a large trial designed specifically for that age group. Without longer follow-up, the age-related finding remains a pointer, not a basis for prescribing NMN.

Evidence stays narrow

The way the trials were set up limited what could be concluded, largely because most studies ran for only four to 12 weeks.

Brief follow-up can detect early shifts in blood pressure, but it cannot show whether heart attacks or strokes are prevented over the longer term.

Most participants had mild, early rises in pressure, and none of the trials included people with moderate or severe high blood pressure.

That makes the findings more applicable to prevention than to advanced disease or urgent treatment.

Lifestyle still leads

Proven lifestyle measures, including Dietary Approaches to Stop Hypertension (DASH), still outperform NMN by a wide margin.

In a large trial, the DASH diet reduced the top blood pressure number by a clearly bigger amount than a standard diet.

Regular aerobic activity has also produced consistent reductions in that top figure across dozens of clinical trials.

Clinical guidance continues to prioritise DASH-style eating, physical activity, weight management, and lower sodium intake ahead of supplements for controlling blood pressure.

Experts urge restraint

Independent specialists viewed the result as interesting, but not strong enough to displace proven care from the outset.

“NMN supplementation is an intriguing area of research because it targets NAD+ metabolism and cellular aging pathways,” said Lauri Wright, Ph.D., RDN, director of nutrition programs and associate professor at the University of South Florida College of Public Health.

Wright said the evidence so far suggests only small improvements in blood pressure and stressed that more research is needed.

Her caution fits the underlying data, since blood pressure was frequently a secondary outcome rather than the primary question.

Supplement labels overpromise

Retail marketing can turn a faint signal from small trials into claims that the evidence does not support.

Dietary supplements are not required to receive US Food and Drug Administration approval for safety or effectiveness before they are sold, even though they are marketed to add nutrients or other compounds.

Across studies, daily doses ranged from 250 to 1,500 mg, but the trials did not identify an optimal dose for use over many years.

These regulatory gaps matter because blood-pressure claims may encourage people to postpone care that is already known to work.

Patients need context

People who already take blood pressure medicines should be particularly careful, because even small additional reductions could add to the effects of prescribed drugs.

A clinician can review home readings, timing of medicines, kidney function, and other drivers of rising pressure before recommending any changes.

Adults whose readings are already normal have less scope to benefit, so the same capsule may produce no measurable effect.

Until more robust trials are available, decisions should be guided by risk, age, current measurements, and individual medical history-not by marketing.

Next trials matter

The latest evidence draws a straightforward boundary: NMN may slightly nudge blood pressure down, but it has not shown heart protection so far.

To justify any clinical role, future studies will need larger numbers of participants, longer follow-up, and hard outcomes such as heart attack or stroke data.